ReviewMultiple sclerosis journal - experimental, translational and clinical
Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.
Review in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: B-cell depleting therapies are used for MS, autoimmune disorders, renal disease and hematological malignancies but increase infection susceptibility. Objective: To describe two cases of enterovirus meningoencephalitis in patients receiving B-cell depleting therapy and review anti-CD20-associated cases, detailing diagnosis, treatment, and outcomes. Methods: We present two cases, one with MS and one with minimal change disease, and review 40 additional anti-CD20 cases. Demographic, clinical, laboratory, neuroimaging, treatment, and outcomes were abstracted. Neuro-QoL measures were analyzed. Results: Our cases were diagnosed by CSF multiplex PCR and treated with IVIg; one also received methylprednisolone and pocapavir. Persistent sequelae included dysarthria, cognitive impairment, nystagmus, pain, and reduced Neuro-QoL scores. Of 42 cases, 34 were associated with rituximab and eight with ocrelizumab. CSF PCR or molecular testing detected enterovirus in 39 cases; three required alternative specimens/sites. IVIg or subcutaneous immunoglobulin (SCIg) was used in 36 cases, steroids in seven, fluoxetine in six, pocapavir in two, pleconaril in two, and ribavirin/favipiravir in one. Outcomes included recovery in 11, sequelae in 19, and death in 12. Conclusions: Enterovirus infection in B-cell depleted patients may cause severe CNS involvement. CSF PCR aids diagnosis, though alternative specimens may be required. Early IVIg and investigational antivirals may be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.